News

CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2…

Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform

We are proud to have been honored with the award from the Federal State Government of Mecklenburg-Vorpommern in the category ‘Company Development’. We…

CENTOGENE announced today a partnering with the Medical Faculties of the Universities of Greifswald and Rostock for the research project, “Development…

CENTOGENE announced today the opening of its first U.S. based rare disease laboratory in Cambridge, Massachusetts. The new facility, opening on August…

CENTOGENE, driving the diagnostic workflows and individualized therapeutic decisions not only in rare diseases but also in oncological setups is proud…

CENTOGENE, the worldwide leader in using genetic and proteomic knowledge to enable patients, clinicians and pharmaceutical partners to identify and…

CENTOGENE, the worldwide leader in using genetic and proteomic knowledge to enable patients, clinicians and pharmaceutical partners to identify and…

Collaboration Builds on Genetic Identification of Patients with Sjögren-Larsson Syndrome (SLS) in a Worldwide Cohort Enabling SLS Patients to Benefit…

Dr. Arndt Rolfs talks at ECRD about speeding up the rare disease knowledge and information eco-system based on proteomic screening tools